General Intermediates of Canada, an Alberta Biotech Company, Receives Canadian Government Funding for Immuno-Oncology Project

Edmonton, Alberta (ots/PRNewswire) -

Edmonton's GIC in pursuit of new immuno-oncology therapy

Edmonton's General Intermediates of Canada Inc. (GIC) announced
today that they have received conditional funding from the National
Research Council of Canada Industrial Research Assistance Program
(NRC IRAP) related to their discovery of a new immuno-oncology
compound that could play a role in the fight against cancer.

The company is currently conducting studies on a family of
compounds targeted towards the Adenosine 2a receptor. In tumors,
adenosine stops T-cells from destroying cancer cells. It is felt that
by blocking A2a receptors, the anti-cancer response of T-cells will
improve and trigger the body's immune system to fight the tumour.

"The blockade of A2a represents the next generation of cancer
immuno-therapy. A lot of research and investment dollars have flowed
into this space in the last several years and we feel our family of
compounds addresses the outstanding needs in this area. This funding
from the NRC IRAP will allow us to finalize the last bit of
pre-clinical work we have outstanding," said GIC's lead scientist,
Dr. Glenn Weagle.

GIC's work on A2a follows on the heels of another highly
successful NRC IRAP project they did which concluded in 2016. That
project was related to providing a starting material for a new cancer
drug under development by a large, multi-national pharmaceutical
company.

"GIC has a long-standing reputation in the pharma industry for
making high quality intermediates, particularly those that are
difficult to make," said Weagle. "We are now taking that expertise
and shifting our focus towards new pharmaceuticals. Our early results
are very positive and we are excited to bring this compound forward
in the fight against cancer."

About General Intermediates of Canada Inc.: GIC has been a
contract manufacturer of small molecules for over 35 years. The
molecules synthesized by GIC are the starting materials in drugs for
a wide variety of diseases and treatments, including those for MS,
Parkinson's disease, asthmatics, anti-virals, and chemotherapeutics.
In addition, GIC has world-leading expertise in the production of
ultra-pure nucleosides for the drug and high-tech industries.

Contacts:

Dr. Glenn Weagle

17319 108 Ave NW

Edmonton, Alberta T5S 1G2

+1-780-483-2783

General Intermediates of Canada Inc.

Twitter: @GIC_News

news@generalintermediates.com

ots Originaltext: General Intermediates of Canada
Im Internet recherchierbar: http://www.presseportal.de

Original-Content von: General Intermediates of Canada, übermittelt durch news aktuell